盆腔炎2号方治疗湿热瘀结型慢性盆腔炎临床疗效  

Clinical efficacy of No.2 pelvic inflammation formulation on chronic pelvic inflammatory disease with dampness heat and stasis

作　　者：洪寅雯 柏亮珍 周玉珍 HONG Yinwen

机构地区：[1]苏州市中西医结合医院,江苏苏州215000

出　　处：《中医临床研究》2021年第29期108-111,共4页Clinical Journal Of Chinese Medicine

摘　　要：目的:探讨盆腔炎2号方治疗湿热瘀结型慢性盆腔炎临床疗效。方法:将2016年1月-2020年6月苏州市中西医结合医院妇产科收治的78例湿热瘀结型慢性盆腔炎患者随机分为治疗组41例和对照组37例。治疗组采用盆腔炎2号方灌肠,对照组采用甲硝唑灌肠。观察两组治疗1个月时血清C反应蛋白浓度、子宫血流动力学、中医证候积分和临床疗效。结果:治疗后,两组患者C反应蛋白浓度均显著低于治疗前,差异有统计学意义(P<0.05);治疗组患者C反应蛋白浓度低于对照组(P<0.05),但无临床意义。两组患者治疗后子宫动脉收缩期最大流速显著高于治疗前,搏动指数和血管阻力指数均显著低于治疗前(P<0.05);治疗组患者子宫动脉收缩期最大流速高于对照组,血管阻力指数低于对照组(P<0.05);两组搏动指数值差异无统计学意义(P>0.05)。两组患者治疗后下腹痛、腰骶部酸痛和白带异常评分均显著低于治疗前(P<0.05);治疗组患者下腹痛、腰骶部酸痛和白带异常评分低于对照组(P<0.05);治疗组总有效率显著高于对照组(P<0.05)。结论:盆腔炎2号方能有效治疗湿热瘀结型慢性盆腔炎。Objective:To investigate the clinical efficacy of No.2 pelvic inflammation formulation on chronic pelvic inflammatory disease with dampness,heat and stasis.Methods:Seventy-eight patients with chronic pelvic inflammatory disease with dampness,heat and stasis treated in our hospital from January 2016 to June 2020 were randomly divided into the treatment group(41 cases)and the control group(37 cases).Patients in the treatment group were treated with No.2 pelvic inflammation formulation,as well as patients in the control group were treated with metronidazole.The serum C-reactive protein(CRP)concentration,uterine hemodynamic indexes,TCM syndrome scores and clinical efficacy were observed at 1 month after treatment.Results:After treatment,the CRP concentrations in the two groups were significantly lower than those before treatment(P<0.05).The CRP concentration in the treatment group was lower than that in the control group(P<0.05).However,there was no clinical significance.After treatment,the peak systolic velocity(PSV)of uterine artery in the two groups were significantly higher than those before treatment,and the pulsatility index(PI)and vascular resistance index(RI)were significantly lower than those before treatment(P<0.05).PSV in the treatment group was higher than the control group,and RI was lower than that in the control group,(P<0.05).There was no significant difference in PI between the two groups(P>0.05).After treatment,the scores of lower abdominal pain,lumbosacral soreness,and abnormal leucorrhea in the two groups were significantly lower than those before treatment(P<0.05).The scores of lower abdominal pain,lumbosacral soreness,and abnormal leucorrhea in the treatment group was lower than those in the control group(P<0.05).The total efficiency in the treatment group was higher than the control group(P<0.05).Conclusion:No.2 pelvic inflammation formulation can effectively treat chronic pelvic inflammatory disease with dampness,heat and stasis.

关 键 词：盆腔炎 湿热瘀结 吴门医派 络病理论 

分 类 号：R711.33[医药卫生—妇产科学]